This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): sorafenib tosylate, BAY 43-9006
Description: Nexavar (Sorafenib) is an oral multi-kinase inhibitor that targets serine/threonine and receptor tyrosine kinases in both the tumor cell and the tumor vasculature. Nexavar targets upstream receptor tyrosine kinases VEGFR-2, VEGFR-3, PDGFR-beta, KIT, FLT3, and RET. It also inhibits downstream serine/threonine kinases CRAF and BRAF, thus blocking the oncogenic activity of Ras and Raf.
Revenue splits for this drug are BioMedTracker estimates.
Onyx and Bayer partnered in 1994 to develop anti-cancer compounds that inhibit proteins in the ras signaling pathway. Nexavar was identified as part of this collaboration. Onyx and Bayer are splitting development costs for Nexavar and have equal profit sharing, 50:50 profit sharing in the United States and nearly 50% profit sharingworldwide except for in Japan. Bayer is funding 100 percent of development costs in Japan and will pay Onyx a 7% royalty on any sales in Japan (due to the structure of the BioMedTracker model for ONXX, the BioMedTracker estimated revenue split for this drug assumes a 10% royalty).
In October 2011, Onyx and Bayer restructured their partnership for the global development and marketing of Nexavar (sorafenib). Onyx and Bayer are free to use their respective Nexavar sales forces to promote regorafenib and additional products outside of the collaboration in the future. Bayer will purchase...See full deal structure in Biomedtracker
Partners: Bayer AG
Additional information available to subscribers only: